The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects
(1999) In Journal of Bone and Mineral Research 14(4). p.555-560- Abstract
- We assessed the serum concentration of gamma-carboxylated osteocalcin (OC), total OC, and full-length OC in a clinical setting of 37 patients on continuous warfarin treatment (international normalized ratio 2.0-3.8). A comparison was done with the results from 30 untreated age-matched controls. Four monoclonal antibodies, previously generated and characterized as to their ability to recognize different human OC forms and fragments, were used in three two-site immunofluorometric assays. The warfarin-treated patients had significantly lower levels of carboxylated OC 4.9 +/- 3.8 (+/- 1 SD) ng/ml compared with the controls 13.1 +/- 9.7 (p < 0.0001). There was no difference in the levels of total OC or full-length OC between the two groups... (More)
- We assessed the serum concentration of gamma-carboxylated osteocalcin (OC), total OC, and full-length OC in a clinical setting of 37 patients on continuous warfarin treatment (international normalized ratio 2.0-3.8). A comparison was done with the results from 30 untreated age-matched controls. Four monoclonal antibodies, previously generated and characterized as to their ability to recognize different human OC forms and fragments, were used in three two-site immunofluorometric assays. The warfarin-treated patients had significantly lower levels of carboxylated OC 4.9 +/- 3.8 (+/- 1 SD) ng/ml compared with the controls 13.1 +/- 9.7 (p < 0.0001). There was no difference in the levels of total OC or full-length OC between the two groups of patients. A strong correlation was found between the serum concentration of carboxylated OC and total OC, both for the warfarin-treated patients (r = 0.98) and for the controls (r = 0.99). There was a distinct cut-off level at 0.80, in the quotient carboxylated OC/total OC, at which all warfarin-treated patients fell below and all controls above this level. Hence, the concentration or ratio of serum gamma-carboxylated OC in clinical settings such as warfarin-treated patients could be measured using two-site immunoassays. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1114957
- author
- Obrant, Karl LU ; Kakonen, S M ; Astermark, Jan LU ; Lilja, Hans LU ; Lovgren, T ; Åkesson, Kristina LU and Pettersson, K
- organization
- publishing date
- 1999
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Bone and Mineral Research
- volume
- 14
- issue
- 4
- pages
- 555 - 560
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:10234576
- scopus:0344628892
- ISSN
- 1523-4681
- DOI
- 10.1359/jbmr.1999.14.4.555
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Clinical and Molecular Osteoporosis Research Unit (013242930), Emergency medicine/Medicine/Surgery (013240200), Clinical Chemistry, Malmö (013016000)
- id
- 140625d3-f0be-4f00-9533-792f7807d55a (old id 1114957)
- date added to LUP
- 2016-04-01 12:00:49
- date last changed
- 2024-02-06 17:35:17
@article{140625d3-f0be-4f00-9533-792f7807d55a, abstract = {{We assessed the serum concentration of gamma-carboxylated osteocalcin (OC), total OC, and full-length OC in a clinical setting of 37 patients on continuous warfarin treatment (international normalized ratio 2.0-3.8). A comparison was done with the results from 30 untreated age-matched controls. Four monoclonal antibodies, previously generated and characterized as to their ability to recognize different human OC forms and fragments, were used in three two-site immunofluorometric assays. The warfarin-treated patients had significantly lower levels of carboxylated OC 4.9 +/- 3.8 (+/- 1 SD) ng/ml compared with the controls 13.1 +/- 9.7 (p < 0.0001). There was no difference in the levels of total OC or full-length OC between the two groups of patients. A strong correlation was found between the serum concentration of carboxylated OC and total OC, both for the warfarin-treated patients (r = 0.98) and for the controls (r = 0.99). There was a distinct cut-off level at 0.80, in the quotient carboxylated OC/total OC, at which all warfarin-treated patients fell below and all controls above this level. Hence, the concentration or ratio of serum gamma-carboxylated OC in clinical settings such as warfarin-treated patients could be measured using two-site immunoassays.}}, author = {{Obrant, Karl and Kakonen, S M and Astermark, Jan and Lilja, Hans and Lovgren, T and Åkesson, Kristina and Pettersson, K}}, issn = {{1523-4681}}, language = {{eng}}, number = {{4}}, pages = {{555--560}}, publisher = {{Wiley-Blackwell}}, series = {{Journal of Bone and Mineral Research}}, title = {{The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects}}, url = {{http://dx.doi.org/10.1359/jbmr.1999.14.4.555}}, doi = {{10.1359/jbmr.1999.14.4.555}}, volume = {{14}}, year = {{1999}}, }